Table 3.

The incidence and proportion of adverse events (AEs) in vaccinees after the 1^st and 2^nd dose of inactivated vaccine.

Type of AEs	After the 1st dose, N = 1392			After the 2nd dose, N = 1047
	No of vaccinees	Incidence (%)	Proportion (%)	No of vaccinees	Incidence (%)	Proportion (%)
Total No of Any AEs	532	38.2	100	325	31.0	100.0
Local AEs*	398	28.6	74.8	272	26.0	83.7
With no other AEs	256	18.4	48.1	219	20.9	67.4
With other AEs	142	10.2	26.7	53	5.1	16.3
Headache, dizziness, insomnia	137	9.8	25.8	50	4.8	15.4
With no other event	79	5.7	14.9	31	3.0	9.5
With any other event	58	4.2	10.9	19	1.8	5.9
Flu-like events	87	6.3	16.4	34	3.2	10.5
Fever (ºC)	30	2.15	5.64	9	0.9	2.8
≥39.0	1	0.07	0.19	0	0	0
38–38.9	2	0.14	0.38	1	0.1	0.3
<38	27	1.94	5.07	8	0.8	2.5
Loss of appetite, nausea, vomiting, abdominal pain, or diarrhea	43	3.1	8.1	11	1.1	3.4
With no other event	22	1.6	4.1	4	0.4	1.2
With any other event	21	1.5	4.0	7	0.7	2.2
Cough, sputum, shortness of breath	16	1.1	3.0	7	0.7	2.2
With no other event	9	0.6	1.7	4	0.4	1.2
With any other event	7	0.5	1.3	3	0.3	1.0
Skin allergic events	19	1.4	3.6	8	0.8	2.5
With no other event	8	0.6	1.5	6	0.6	1.9
With any other event	11	0.8	2.1	2	0.2	0.6
Menstrual changes	22	2.1†	4.1	10	1.0†	3.1
Menstruation delay	15	1.4	2.8	6	0.6	1.9
Early menstruation	4	0.4	0.7	3	0.3	0.9
Menorrhagia	2	0.2	0.4	1	0.1	0.3
Prolonged period	1	0.1	0.2	0	0.0	0.0
Severity of AEs
Mild	505	36.3	94.9	316	30.2	97.2
Moderate	27	1.9	5.1	9	0.9	2.8
Severe	0	0	0	0	0	0

*Pain, erythema, swelling, or itch on injection site. †The denominators were those women at the age of ≤50 y who were assumed to still have menstruation as the average age of menopause in China is around 50 y. 1073 and 943 women with the age ≤50 y accepted the 1st and 2nd vaccination respectively.